-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, CQk7MeXeahNbEEPZPwvayqhs7tfYPjLfBiQ1dCLWEKUyYTzorYZc04SWCmQlZnEk xgeZw2y/lMKQSJQ/ofkVoQ== 0000950103-01-501360.txt : 20010911 0000950103-01-501360.hdr.sgml : 20010911 ACCESSION NUMBER: 0000950103-01-501360 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20010531 FILED AS OF DATE: 20010910 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: MEDICINES CO/ MA CENTRAL INDEX KEY: 0001113481 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043324394 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-31191 FILM NUMBER: 1734350 BUSINESS ADDRESS: STREET 1: ONE CAMBRIDGE CTR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 6172259099 COMPANY DATA: COMPANY CONFORMED NAME: HUSAIN FAZLE M CENTRAL INDEX KEY: 0001091618 STANDARD INDUSTRIAL CLASSIFICATION: [] DIRECTOR FILING VALUES: FORM TYPE: 4 BUSINESS ADDRESS: STREET 1: C/O DAVIS, POLK & WARDWELL STREET 2: 450 LEXINGTON AVENUE CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 2124504403 MAIL ADDRESS: STREET 1: 450 LEXINGTON AVENUE CITY: NEW YORK STATE: NY ZIP: 10017 4 1 aug2301_4-husain.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP FORM 4 [ ] Check this box if no longer OMB APROVAL subject to Section 16. Form 4 or OMB NUMBER: 3235-0287 Form 5 obligations may continue. Expires: September 30, 1998 See Instruction 1(b). Estimated average burden hours per response........0.5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940 (Print or Type Responses) 1. Name and Address of Reporting Person* Husain M. Fazle - ----------------------------------------------------------------------------- (Last) (First) (Middle) c/o The Medicines Company One Cambridge Center - ----------------------------------------------------------------------------- (Street) Cambridge MA 02142 - ----------------------------------------------------------------------------- (City) (State) (Zip) 2. Issuer Name and Ticker or Trading Symbol The Medicines Company (MDCO) - ----------------------------------------------------------------------------- 3. I.R.S. or Social Security Number of Reporting Person (Voluntary) - ----------------------------------------------------------------------------- 4. Statement for Month/Year 05/01 - ----------------------------------------------------------------------------- 5. If Amendment, Date of Original (Month/Day/Year) - ----------------------------------------------------------------------------- 6. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner --- --- Officer (give title below) Other (specify below) --- --- - ---------------------------------------------------------------------------- 7. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person - ---- Form filed by More than One Reporting Person - ---- Table I -- Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security 2. Trans- 3. Trans- 4. Securities Acquired 5. Amount of Securities 6. Ownership 7. Nature of (Instr. 3) action action (A) or Disposed of Beneficially Owned Form: Direct Indirect Date Code (D) (Instr. 3, 4 at End of Month (D) or In- Beneficial (Instr.8) and 5) (Instr. 3 and 4) direct (I) Ownership (Month/ (Instr. 4) (Instr. 4) Day/ (A) or Year) Code V Amount (D) Price - ------------------------- --------- ---- --- ------- --- --------- -------------------- -------------- ------------- Common Stock 1,952,774(1) I(2) through partnerships Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4(b)(v). (Over) SEC 1474 (7-96)
FORM 4 (continued) Table II -- Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of 2. Conversion or 3. Transaction Date 4. Transaction 5. Number of 6. Date Exercisable and Derivative Exercise Price (Month/Day/Year) Code Derivative Expiration Date Security of Derivative (Instr. 8) Securities (Month/Day/Year) (Instr. 3) Security Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) Date Expiration Code V (A) (D) Exercisable Date - ------------------------------------------------------------------------------------------------------------------------------------ Warrants (Right to Buy)(4) $ 5.92 Immed. 10/18/04 Warrants (Right to Buy)(4) $ 5.92 Immed. 03/02/05 Option (Right to Buy) $13.80 05/31/01 A V 7,500 (3) 05/31/11
1. Title of 7. Title and Amount of 8. Price of 9. Number of 10. Ownership 11. Nature of Derivative Underlying Securities Derivative Derivative Form of Indirect Security (Instr. 3 and 4) Security Securities Derivative Beneficial (Instr. 3) (Instr. 5) Beneficially Security: Ownership Amount Owned at End Direct (D) (Instr. 4) or of Month or Indirect Number (Instr. 4) (I) of (Instr. 4) Title Shares - ------------------------------------------------------------------------------------------------------------------------------------ Warrants (Right to Buy)(4) Common Stock 108,878 108,878 I(2) through partnerships Warrants (Right to Buy)(4) Common Stock 191,334 191,334 I(2) through partnerships Option (Right to Buy) Common Stock 7,500 7,500 D Explanation of Responses: 1. The reported securities owned by the Funds (defined below) as at 05/31/01. 2. The Reporting Person is a managing member of Morgan Stanley Venture Partners III, L.L.C., the general partner (the "General Partner") of Morgan Stanley Venture Partners III, L.P., Morgan Stanley Venture Investors III, L.P., and The Morgan Stanley Venture Partners Entrepreneur Fund, L.P (collectively, the "Funds"). The Reporting Person disclaims any beneficial ownership of any of the securities owned by the Funds except to the extent of his proportionate pecuniary interest in the General Partner. 3. The option vests in 48 equal monthly installments beginning on June 30, 2001. 4. In the report filed for June 2001, the warrants had been included in the total number of securities reported in Table I. **Intentional misstatements or omissions of facts constitute Federal Criminal /s/ Debra Abramovitz 09/06/01 Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). ------------------------------- ------------ **Signature of Reporting Person Date Debra Abramovitz, Attorney-in- Fact for M. Fazle Husain Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. Page 2 SEC 1474 (7-96)
-----END PRIVACY-ENHANCED MESSAGE-----